EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Treatment‐related neuroendocrine prostate cancer with BRCA2 germline mutation treated with olaparib

Riko Ikeda iD, Yoh Matsuoka iD, Masaharu Inoue, Ayataka Ishikawa, Kiwamu Akagi, Yukio Kageyama

IJU Case Reports · 2024-03 · 7 (2) · 115-119

DOI: 10.1002/iju5.12679 ↗

Kurz gefasst

Fallbericht in der Zeitschrift IJU Case Reports, online erschienen am 08.12.2023. Verfasst von Riko Ikeda und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology Saitama Cancer Center Saitama Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The efficacy of olaparib for treatment‐related neuroendocrine prostate cancer is unknown. Here, we report a case of treatment‐related neuroendocrine prostate cancer with a BRCA2 mutation that was treated with olaparib with 1‐year efficacy. Case presentation A 75‐year‐old man initially diagnosed with prostate adenocarcinoma developed treatment‐related neuroendocrine prostate cancer after 10‐year androgen deprivation therapy. Despite the initial temporary effects of etoposide and carboplatin, the patient experienced prostate bed tumor recurrence 1 year after chemotherapy cessation. FoundationOne® detected a BRCA2 gene mutation, and olaparib was initiated after repeating one chemotherapy course using the same chemotherapeutic agents. The patient received olaparib with sustained tumor regression for 1 year without severe side effects.

Conclusion

Olaparib may be the treatment of choice for treatment‐related neuroendocrine prostate cancer in patients with BRCA mutations.

Schlagwörter

Stichwörter der Autor:innen

BRCA2castration‐resistantneuroendocrine tumorpoly(ADP‐ribose) polymerase inhibitorsprostate cancer

Autor:innen und Institutionen

  • Department of Urology Saitama Cancer Center Saitama Japan.
  • Department of Pathology Saitama Cancer Center Saitama Japan.
  • Department of Molecular Diagnosis and Cancer Prevention Saitama Cancer Center Saitama Japan.

ORCID-Profile: Riko Ikeda, Yoh Matsuoka

Zitieren

APA

Ikeda, R., Matsuoka, Y., Inoue, M., Ishikawa, A., Akagi, K., & Kageyama, Y. (2024). Treatment‐related neuroendocrine prostate cancer with BRCA2 germline mutation treated with olaparib. IJU Case Reports, 7(2), 115-119. https://doi.org/10.1002/iju5.12679

Vancouver

Ikeda R, Matsuoka Y, Inoue M, Ishikawa A, Akagi K, Kageyama Y. Treatment‐related neuroendocrine prostate cancer with BRCA2 germline mutation treated with olaparib. IJU Case Reports. 2024;7(2):115-119. doi:10.1002/iju5.12679

BibTeX
@article{Ikeda2024,
  author = {Ikeda, Riko and Matsuoka, Yoh and Inoue, Masaharu and Ishikawa, Ayataka and Akagi, Kiwamu and Kageyama, Yukio},
  title = {Treatment‐related neuroendocrine prostate cancer with BRCA2 germline mutation treated with olaparib},
  journal = {IJU Case Reports},
  year = {2024},
  volume = {7},
  number = {2},
  pages = {115--119},
  doi = {10.1002/iju5.12679}
}
Kostenlos starten →